# US 2004/0082518 A1 · New use of melagatran

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082518 A1
- Document ID: US20040082518A1
- Status: Published application
- Kind: A1
- Application number: 10/685,003
- Filed: 2003-10-15
- Published: 2004-04-29
- Earliest claimed: 1999-01-13
- Assignees: AstraZeneca AB
- Inventors: Ian Kirk
- Web page: https://patentgrep.com/patent/US20040082518A1

## CPC

- A61K 31/397: having four-membered rings, e.g. azetidine
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

According to the invention there is provided the use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of a medicament for the treatment of inflammation.

## Claims

### Claim 1

The use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of a medicament for the treatment of inflammation.

### Claim 2

The use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of an antiinflammatory medicament.

### Claim 3

A method of treatment of inflammation which comprises administering a therapeutically effective amount of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, to a patient in need of such treatment.

### Claim 4

A pharmaceutical formulation for use in the treatment of inflammation comprising an effective amount of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof.

### Claim 5

Use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, for the treatment of inflammation by administering melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, to a patient.

### Claim 6

The use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the treatment of inflammation.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A use, method or formulation as claimed in any one of claims 1 to 6 (as appropriate), wherein the treatment is of inflammation in patients with, or at risk of, a disease in which inhibition of thrombin is desired or required.

### Claim 8 (depends on 7)

A use, method or formulation as claimed in claim 7, wherein the disease is one in which inflammation plays a part in triggering coagulation.

### Claim 9 (depends on 7, 8)

A use, method or formulation as claimed in claim 7 or claim 8, wherein the patient has, or is at risk of, a thrombus.

### Claim 10

A use, method or formulation as claimed in any one of the preceding claims, wherein the prodrug is the formula
R1O2C—CH2—(R)Cgl-Aze-Pab-OH
wherein R1 represents linear or branched C1-6 alkyl and the OH group replaces one of the amidino hydrogens in Pab.

### Claim 11 (depends on 10)

A use, method or formulation as claimed in claim 10, wherein R1 represents methyl, ethyl or propyl.
